Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, non-randomized efficacy and safety of anlotinib-pembrolizumab combination therapy as a treatment for refractory or recurrent high-grade serous ovarian cancer patients

Next Previous
Trial Profile

A prospective, non-randomized efficacy and safety of anlotinib-pembrolizumab combination therapy as a treatment for refractory or recurrent high-grade serous ovarian cancer patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Catequentinib (Primary) ; Pembrolizumab (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use

Most Recent Events

  • 01 Jul 2022 New trial record
  • 07 Jun 2022 Primary endpoint (overall survival (OS)) has been met, according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
  • 07 Jun 2022 Primary endpoint (progression-free survival (PFS) ) has been met, according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top